BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 27510762)

  • 1. Performance of PI-RADS version 1 versus version 2 regarding the relation with histopathological results.
    Auer T; Edlinger M; Bektic J; Nagele U; Herrmann T; Schäfer G; Aigner F; Junker D
    World J Urol; 2017 May; 35(5):687-693. PubMed ID: 27510762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
    Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
    Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of PI-RADS v2 for the Detection of Prostate Cancer.
    Kasel-Seibert M; Lehmann T; Aschenbach R; Guettler FV; Abubrig M; Grimm MO; Teichgraeber U; Franiel T
    Eur J Radiol; 2016 Apr; 85(4):726-31. PubMed ID: 26971415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: Prostate Imaging Reporting and Data System Version 1 versus Version 2.
    Feng ZY; Wang L; Min XD; Wang SG; Wang GP; Cai J
    Chin Med J (Engl); 2016 Oct; 129(20):2451-2459. PubMed ID: 27748338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Implications of PI-RADS Version 1 and Updated Version 2 on the Scoring of Prostatic Lesions in Multiparametric MRI].
    Haas M; Günzel K; Penzkofer T; Maxeiner A; Fischer T; Miller K; Hamm B; Asbach P; Cash H
    Aktuelle Urol; 2016 Sep; 47(5):383-7. PubMed ID: 27680189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Head-to-head comparison of PI-RADS v2 and PI-RADS v1.
    Polanec S; Helbich TH; Bickel H; Pinker-Domenig K; Georg D; Shariat SF; Aulitzky W; Susani M; Baltzer PA
    Eur J Radiol; 2016 Jun; 85(6):1125-31. PubMed ID: 27161062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standardized Reporting of Prostate MRI: Comparison of the Prostate Imaging Reporting and Data System (PI-RADS) Version 1 and Version 2.
    Tewes S; Mokov N; Hartung D; Schick V; Peters I; Schedl P; Pertschy S; Wacker F; Voshage G; Hueper K
    PLoS One; 2016; 11(9):e0162879. PubMed ID: 27657729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis.
    Junker D; Quentin M; Nagele U; Edlinger M; Richenberg J; Schaefer G; Ladurner M; Jaschke W; Horninger W; Aigner F
    World J Urol; 2015 Jul; 33(7):1023-30. PubMed ID: 25081011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of PI-RADS version 2 and PI-RADS version 2.1 for the detection of transition zone prostate cancer.
    Tamada T; Kido A; Takeuchi M; Yamamoto A; Miyaji Y; Kanomata N; Sone T
    Eur J Radiol; 2019 Dec; 121():108704. PubMed ID: 31669798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigating the role of DCE-MRI, over T2 and DWI, in accurate PI-RADS v2 assessment of clinically significant peripheral zone prostate lesions as defined at radical prostatectomy.
    Taghipour M; Ziaei A; Alessandrino F; Hassanzadeh E; Harisinghani M; Vangel M; Tempany CM; Fennessy FM
    Abdom Radiol (NY); 2019 Apr; 44(4):1520-1527. PubMed ID: 30361870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of PI-RADS 2, ADC histogram-derived parameters, and their combination for the diagnosis of peripheral zone prostate cancer.
    Lin WC; Westphalen AC; Silva GE; Chodraui Filho S; Reis RB; Muglia VF
    Abdom Radiol (NY); 2016 Nov; 41(11):2209-2217. PubMed ID: 27364781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic value of PI-RADS V1 and V2 using multiparametric MRI in transition zone prostate clinical cancer.
    Wang X; Bao J; Ping X; Hu C; Hou J; Dong F; Guo L
    Oncol Lett; 2018 Sep; 16(3):3201-3206. PubMed ID: 30127915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
    Ziayee F; Ullrich T; Blondin D; Irmer H; Arsov C; Antoch G; Quentin M; Schimmöller L
    PLoS One; 2021; 16(4):e0249532. PubMed ID: 33819295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
    Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
    J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
    Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
    World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI-RADS v2 and periprostatic fat measured on multiparametric magnetic resonance imaging can predict upgrading in radical prostatectomy pathology amongst patients with biopsy Gleason score 3 + 3 prostate cancer.
    Zhai L; Fan Y; Sun S; Wang H; Meng Y; Hu S; Wang X; Yu W; Jin J
    Scand J Urol; 2018; 52(5-6):333-339. PubMed ID: 30895901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preliminary applicability evaluation of Prostate Imaging Reporting and Data System version 2 diagnostic score in 3.0T multi-parameters magnetic resonance imaging combined with prostate specific antigen density for prostate cancer].
    Zuo MZ; Zhao WL; Wei CG; Zhang CY; Wen R; Gu YF; Li MJ; Zhang YY; Wu JF; Li X; Shen JK
    Zhonghua Yi Xue Za Zhi; 2017 Dec; 97(47):3693-3698. PubMed ID: 29325321
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
    Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
    Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI-RADS v2 and ADC values: is there room for improvement?
    Jordan EJ; Fiske C; Zagoria R; Westphalen AC
    Abdom Radiol (NY); 2018 Nov; 43(11):3109-3116. PubMed ID: 29550953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.